Yuhan Overview
- Year Founded
-
1926
- Status
-
Public
- Employees
-
2,123
- Stock Symbol
-
000100
- Investments
-
47
- Share Price
-
$59.70
- (As of Thursday Closing)
Yuhan General Information
Description
Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.
Contact Information
Website
www.yuhan.co.krCorporate Office
- 74, Noryangjin-ro
- Dongjak-gu
- Seoul, 06934
- South Korea
Corporate Office
- 74, Noryangjin-ro
- Dongjak-gu
- Seoul, 06934
- South Korea
Yuhan Stock Performance
As of 12-Nov-2026, Yuhan’s stock price is $59.70. Its current market cap is $4.45B with 74.8M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $59.70 | $58.83 | $42.01 - $87.85 | $4.45B | 74.8M | 257K | $2.19 |
Yuhan Financials Summary
As of 30-Jun-2026, Yuhan has a trailing 12-month revenue of $1.57B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,392,109 | 5,845,031 | 6,108,205 | 3,908,032 |
| Revenue | 1,572,652 | 1,536,491 | 1,515,491 | 1,421,840 |
| EBITDA | 246,426 | 210,145 | 95,733 | 133,368 |
| Net Income | 163,366 | 136,374 | 51,807 | 104,171 |
| Total Assets | 2,158,298 | 2,236,740 | 1,997,357 | 2,182,315 |
| Total Debt | 226,525 | 235,884 | 205,729 | 152,615 |
Yuhan Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Yuhan Comparisons
Industry
Financing
Details
Yuhan Competitors (10)
One of Yuhan’s 10 competitors is Celltrion, a Formerly VC-backed company based in Incheon, South Korea.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Celltrion | Formerly VC-backed | Incheon, South Korea | ||||
| Hanmi Pharm | Corporation | Seoul, South Korea | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Roche | Corporation | Basel, Switzerland | ||||
| Samsung Biologics | Corporation | Incheon, South Korea |
Yuhan Patents
Yuhan Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026212481-A1 | Pharmaceutical formulations comprising an anti-egfr/anti-4-1bb bispecific antibody, and dosage and/or administration regimen of the bispecific antibody | Pending | 04-Apr-2025 | ||
| WO-2026049509-A1 | Benzimidazole compounds having glp-1 receptor agonist activity, methods for preparing same, and medical uses thereof | Pending | 28-Aug-2024 | ||
| WO-2026049510-A1 | Thienoimidazole compounds having glp-1 receptor agonist activity, methods for preparing same, and medical uses thereof | Pending | 28-Aug-2024 | ||
| WO-2026024121-A1 | Bicyclic fused-ring derivative or salt thereof and pharmaceutical composition including the same | Pending | 25-Jul-2024 | ||
| WO-2025249917-A1 | Pharmaceutical composition for preventing or treating cancer | Pending | 29-May-2024 | A61P35/00 |
Yuhan Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Yuhan Investments & Acquisitions (47)
Yuhan’s most recent deal was a Later Stage VC with CharmCare for . The deal was made on 19-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CharmCare | 19-Oct-2026 | Later Stage VC | Monitoring Equipment | ||
| NOBO Medicine | 28-Jul-2025 | Later Stage VC | Drug Discovery | ||
| Yuhan Evertis Dental Implants (Shin Hung Company / Yuhan) | 25-Jul-2025 | Joint Venture | Medical Supplies | ||
| Prazer Therapeutics | 09-Mar-2025 | Later Stage VC | Drug Discovery | ||
| Aimedbio | 31-Jul-2024 | Later Stage VC | Drug Discovery |
Yuhan ESG
Risk Overview
Risk Rating
Updated November, 11, 2026
28.71 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Yuhan Exits (11)
Yuhan’s most recent exit was on 31-Jul-2024 from Aimedbio. The exit was categorized as with 6 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Aimedbio | 31-Jul-2024 | Completed |
|
||
| oncoMASTER | 07-Feb-2024 | Completed |
|
||
| ImmuneOncia | 02-Nov-2023 | Completed |
|
||
| ProGen (Drug Discovery) | 05-Apr-2023 | Completed |
|
||
| ImmuneOncia | 16-Jan-2022 | Later Stage VC | Completed |
|
Yuhan Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Wisemedi | Jincheon gun, South Korea | 2003 | |
| Warantec | Seongnam-si, South Korea | 2001 | |
| Yuhan Cosmetics | Osan-si, South Korea | 1992 |
Yuhan FAQs
-
When was Yuhan founded?
Yuhan was founded in 1926.
-
Where is Yuhan headquartered?
Yuhan is headquartered in Seoul, South Korea.
-
What is the size of Yuhan?
Yuhan has 2,123 total employees.
-
What industry is Yuhan in?
Yuhan’s primary industry is Biotechnology.
-
Is Yuhan a private or public company?
Yuhan is a Public company.
-
What is Yuhan’s stock symbol?
The ticker symbol for Yuhan is 000100.
-
What is the current stock price of Yuhan?
As of 12-Nov-2026 the stock price of Yuhan is $59.70.
-
What is the current market cap of Yuhan?
The current market capitalization of Yuhan is $4.45B.
-
What is Yuhan’s current revenue?
The trailing twelve month revenue for Yuhan is $1.57B.
-
Who are Yuhan’s competitors?
Celltrion, Hanmi Pharm, GSK, Roche, and Samsung Biologics are some of the 10 competitors of Yuhan.
-
What is Yuhan’s annual earnings per share (EPS)?
Yuhan’s EPS for 12 months was $2.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
